What Imaging Biometrics does

Imaging Biometrics develops FDA-cleared, MRI-based software applications for the healthcare industry, focused on neuroimaging analysis in neuro-oncology and neurology. The company's product portfolio consists of four core offerings: IB Neuro, a brain tumor analysis software that extracts cerebral blood volume measurements from MRI perfusion scans to predict treatment effectiveness and overall survival in glioblastoma patients; the FTB Mapping Platform, an FDA-cleared MRI-based neuroimaging analysis platform; FTB Express, a neuroimaging module added to the company's distribution channel; and QSMetric, an FDA-cleared MRI software tool that uses quantitative susceptibility mapping to detect subtle brain changes such as microhaemorrhages and iron build-up associated with Alzheimer's disease, multiple sclerosis, and traumatic brain injury. Underlying these products is a quantitative imaging biomarker platform that converts routine MRI scans into clinically validated measurements, with the IB Neuro EAF151 Phase II trial (146 patients across 33 centers) demonstrating a statistically significant association between cerebral blood volume measurements and overall survival in recurrent glioblastoma patients treated with bevacizumab.

Name

Imaging Biometrics

Legal name

Imaging Biometrics Limited

Website

https://imagingbiometrics.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Imaging Biometrics develops FDA-cleared MRI-based neuroimaging software — IB Neuro, FTB Mapping Platform, FTB Express, and QSMetric — that extracts quantitative imaging biomarkers to support brain tumor diagnosis, treatment monitoring, and neurological disease assessment for healthcare clinics and clinical trial sponsors.

Ownership category

akta.pro rank

Product category

Neuroimaging Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI), Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)

Keywords

• MRI neuroimaging software
• Brain tumor imaging
• Quantitative imaging biomarkers
• Cerebral blood volume analysis
• Quantitative susceptibility mapping

Headquarters

HQ city

Elm Grove

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Annual Software License - QSMetric: QSMetric is sold as an annual license to clinics and clinical trial sponsors. The partnership with MedImageMetric plans to develop additional applications combining QSMetric with other imaging technologies and building AI tools to guide treatment decisions.
2. Neuroimaging Software Distribution: Revenue generated through distribution agreement with GE Healthcare for neuroimaging products FTB Express and QSMetric.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Imaging Biometrics develops and sells FDA-cleared MRI-based neuroimaging software that delivers quantitative imaging biomarkers (such as cerebral blood volume and quantitative susceptibility measurements) used by clinicians and clinical trial sponsors to diagnose, characterize, and monitor brain tumors. Its product suite (IB Neuro, FTB Mapping Platform, FTB Express, QSMetric) targets neuro-oncology practice and pharmaceutical trial workflows and is distributed globally through a partnership with GE Healthcare.

Product overview

Imaging Biometrics offers a portfolio of FDA-cleared MRI-based neuroimaging products for brain tumor diagnosis and monitoring. The core offerings include IB Neuro (brain tumor analysis software), the FTB Mapping Platform, FTB Express, and QSMetric. These products work together to provide clinicians with quantitative imaging biomarkers from MRI scans, enabling treatment effectiveness assessment and detection of subtle brain changes associated with various neurological conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• IB Neuro FDA-cleared MRI neuroimaging software that processes dynamic susceptibility contrast (DSC) perfusion MRI scans to compute standardized cerebral blood volume (CBV) maps for brain tumor diagnosis, grading, and treatment monitoring; used by neuroradiologists, oncology clinics, and clinical trial imaging cores.
• FTB Mapping Platform FDA-cleared neuroimaging software platform that delivers quantitative susceptibility mapping (QSM) and related biomarker analysis of brain MR images, supporting neuro-oncology imaging workflows in clinical and research settings.
• FTB Express Processing tool within the FTB product family that streamlines execution of FTB (susceptibility/QSM) biomarkers for faster clinical review, intended for sites that need quicker quantitative neuroimaging reads alongside the full FTB Mapping Platform.
• QSMetric Quantitative susceptibility mapping software for brain MRI analysis, providing standardized QSM measurements used in neuro-oncology research and clinical trial imaging endpoints.

Quantifiable outcome

• Treatment effectiveness can be determined within weeks rather than months using IB Neuro cerebral blood volume measurements
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• GE HealthcarecoreChannel Partner/ Reseller/ Distributor · 10 December 2025Imaging Biometrics expanded its distribution agreement with GE Healthcare to include neuroimaging products FTB Express and QSMetric. The agreement covers additional tools for the diagnosis and monitoring of brain tumor patients. Shares of Imaging Biometrics rose 16% following the announcement, indicating market validation of the partnership's strategic importance.
• MedImageMetriccoreStrategic or Co-development Partner · 16 September 2025Imaging Biometrics partnered with MedImageMetric to commercialize QSMetric, an FDA-cleared MRI software tool that uses quantitative susceptibility mapping to detect subtle brain changes associated with conditions including Alzheimer's disease, multiple sclerosis, and traumatic brain injury. The partnership plans to develop additional applications combining QSMetric with other imaging technologies and building AI tools to guide treatment decisions.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Others

• GE Healthcare: Both the partner that distributes Imaging Biometrics' products and a broader imaging incumbent with growing AI/quantitative imaging capabilities; relevant as both a strategic channel and a potential competitive OEM.

Direct peers

• Brainlab: Provides surgical planning and imaging software for neuro-oncology and radiotherapy. Overlaps with Imaging Biometrics in brain tumor visualization, surgical workflows, and treatment monitoring using MRI-derived data.
• Cortechs.ai: Developer of NeuroQuant, an FDA-cleared quantitative MRI brain analysis tool. Closely comparable to Imaging Biometrics' FTB Mapping and IB Neuro as both provide quantitative neuroimaging biomarkers for clinical and research use in neurology/oncology.
• Quibim: AI platform for medical imaging analysis including quantitative MRI biomarkers for oncology and neurological disease. Comparable product profile and customer base (clinics and pharma/clinical trial sponsors).
• Icometrix: Specializes in AI-based MRI analysis for multiple sclerosis, dementia, and traumatic brain injury, overlapping directly with QSMetric's use cases for MS, Alzheimer's, and TBI monitoring on quantitative susceptibility imaging.

Broad incumbents

• Siemens Healthineers: Major MRI equipment OEM and increasingly embedded AI imaging software (AI-Rad Companion). Comparable end customer (MRI scanner owners) and competes indirectly via OEM-embedded quantitative imaging tools.
• Aidoc: Broad AI imaging portfolio across radiology, with emerging neuroimaging applications. Comparable as an FDA-cleared imaging AI vendor selling enterprise-wide to hospitals, though far broader in scope than IB.

Emerging players

• Blackford Analysis: Medical imaging AI platform curating and deploying third-party algorithms, including neuroimaging. Comparable channel and AI-deployment model relevant to Imaging Biometrics' positioning with GE and other OEMs.
• Viz.ai: AI medical imaging company focused initially on stroke but expanding into other neurovascular and neuroimaging use cases. Comparable as an AI-powered imaging SaaS vendor selling to clinical customers and health systems.
• RapidAI: AI neuroimaging and workflow software primarily for stroke and other neurological conditions. Comparable distribution model and quantitative imaging biomarker positioning, though broader neurology footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imaging Biometrics